Advertisement

Neurotoxicity Research

, Volume 35, Issue 2, pp 441–450 | Cite as

Dynamic Changes in the Estimated Glomerular Filtration Rate Predict All-Cause Mortality After Intravenous Thrombolysis in Stroke Patients

  • Jijun Shi
  • Yuanyuan Liu
  • Yiteng Liu
  • Huihui Liu
  • Jiaping Xu
  • Xia Zhang
  • Shoujiang You
  • Yongjun CaoEmail author
ORIGINAL ARTICLE
  • 62 Downloads

Abstract

Little is known about the prognostic value of the estimated glomerular filtration rate (eGFR) and the effect of dynamic changes in the eGFR on mortality in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT). We aim to investigate the association between the eGFR and dynamic changes in the eGFR after IVT with all-cause mortality in AIS patients. A total of 391 AIS patients treated with IVT between May 2010 and May 2017 were included in the final analysis. Serum creatinine was measured at admission and within 24 h after IVT. The main outcomes included 3-month all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE). During the 3-month follow-up, 37 (9.5%) patients died from all causes. Mortality was associated with a reduced eGFR at admission (adjusted hazard ratio (HR), 4.17; 95% confidence interval (CI), 1.50–11.58; P trend = 0.016) and within 24 h after IVT (adjusted HR, 5.88; 95% CI, 1.41–24.52; P trend = 0.009). Mortality was negatively correlated with increased eGFR after IVT (adjusted HR, 0.70; 95% CI, 0.51–0.96; P trend = 0.027). Additionally, a reduced eGFR after IVT was also associated with increased risk of MACCE (adjusted HR, 3.64; 95% CI, 1.41–9.39; P trend = 0.009). Using a multivariable Cox regression model with restricted cubic splines, we observed an L-shaped association between the eGFR and 3-month all-cause mortality and MACCE and observed a linear association between dynamic changes in the eGFR and 3-month all-cause mortality. A reduced eGFR and dynamic decreases in the eGFR after IVT independently predict 3-month all-cause mortality in AIS patients.

Keywords

Estimated glomerular filtration rate Acute ischemic stroke Mortality Intravenous thrombolysis Recombinant tissue plasminogen activator 

Notes

Acknowledgements

The authors wish to thank the clinical staff for their support in providing data and in contributing to this study.

Sources of Funding

This work was supported by the National Natural Science Foundation of China [grant number 81471195], the Suzhou Clinical Research Center of Neurological Disease [grant number szzx201503], the Second Affiliated Hospital of Soochow University Preponderant Clinic Discipline Group Project Funding [grant number XKQ2015002], and the Suzhou Youth Science and Technology Project [grant number KJXW2015010].

Compliance with Ethical Standards

The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all the participants or from their caregivers.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12640_2018_9970_MOESM1_ESM.docx (20.8 mb)
ESM 1 (DOCX 21327 kb)

References

  1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24:35–41CrossRefGoogle Scholar
  2. Ahmed N, Lees KR, Ringleb PA, Bladin C, Collas D, Toni D, Ford GA, And the SITS Investigators (2017) Outcome after stroke thrombolysis in patients >80 years treated within 3 hours vs >3-4.5 hours. Neurology 89:1561–1568.  https://doi.org/10.1212/WNL.0000000000004499 CrossRefPubMedGoogle Scholar
  3. Carr SJ, Wang X, Olavarria VV, Lavados PM, Rodriguez JA, Kim JS, Lee TH, Lindley RI, Pontes-Neto OM, Ricci S, Sato S, Sharma VK, Woodward M, Chalmers J, Anderson CS, Robinson TG, ENCHANTED Investigators (2017) Influence of renal impairment on outcome for thrombolysis-treated acute ischemic stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) post hoc analysis. Stroke 48:2605–2609.  https://doi.org/10.1161/STROKEAHA.117.017808 CrossRefPubMedGoogle Scholar
  4. Chen CH, Tang SC, Tsai LK, Yeh SJ, Chen KH, Li CH, Hsiao YJ, Chen YW, Yip BS, Jeng JS (2013) Proteinuria independently predicts unfavorable outcome of ischemic stroke patients receiving intravenous thrombolysis. PLoS One 8:e80527.  https://doi.org/10.1371/journal.pone.0080527 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V (2010) Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. Bmj 341:c4986.  https://doi.org/10.1136/bmj.c4986 CrossRefPubMedPubMedCentralGoogle Scholar
  6. Gadalean F, Simu M, Parv F, Vorovenci R, Tudor R, Schiller A, Timar R, Petrica L, Velciov S, Gluhovschi C, Bob F, Mihaescu A, Timar B, Spasovski G, Ivan V (2017) The impact of acute kidney injury on in-hospital mortality in acute ischemic stroke patients undergoing intravenous thrombolysis. PLoS One 12:e0185589.  https://doi.org/10.1371/journal.pone.0185589 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Gensicke H, Zinkstok SM, Roos YB, Seiffge DJ, Ringleb P, Artto V, Putaala J, Haapaniemi E, Leys D, Bordet R, Michel P, Odier C, Berrouschot J, Arnold M, Heldner MR, Zini A, Bigliardi G, Padjen V, Peters N, Pezzini A, Schindler C, Sarikaya H, Bonati LH, Tatlisumak T, Lyrer PA, Nederkoorn PJ, Engelter ST (2013) IV thrombolysis and renal function. Neurology 83:1780–1788.  https://doi.org/10.1212/01.wnl.0000435550.83200.9e CrossRefGoogle Scholar
  8. Gensicke H, Frih AA, Strbian D, Zini A, Pezzini A, Padjen V, Haueter M, Seiffge DJ, Mäkitie L, Traenka C, Poli L, Martinez-Majander N, Putaala J, Bonati LH, Sibolt G, Giovannini G, Curtze S, Beslac-Bumbasirevic L, Vandelli L, Lyrer PA, Nederkoorn PJ, Tatlisumak T, Engelter ST, the Thrombolysis in Stroke Patients (TRISP) Collaborators (2017) Prognostic significance of proteinuria in stroke patients treated with intravenous thrombolysis. Eur J Neurol 24:262–269.  https://doi.org/10.1111/ene.13179 CrossRefPubMedGoogle Scholar
  9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305.  https://doi.org/10.1056/NEJMoa041031 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Hao Z, Yang C, Liu M, Wu B (2014) Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis. Medicine 93:e286.  https://doi.org/10.1097/MD.0000000000000286 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Hrafnkelsdóttir T, Ottosson P, Gudnason T, Samuelsson O, Jern S (2004) Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 44:300–304.  https://doi.org/10.1161/01.HYP.0000137380.91476.fb CrossRefPubMedGoogle Scholar
  12. Hsieh CY, Lin HJ, Sung SF, Hsieh HC, Lai EC, Chen CH (2014) Is renal dysfunction associated with adverse stroke outcome after thrombolytic therapy. Cerebrovasc Dis 37:51–56.  https://doi.org/10.1159/000356348 CrossRefPubMedGoogle Scholar
  13. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947.  https://doi.org/10.1161/STR.0b013e318284056a CrossRefPubMedPubMedCentralGoogle Scholar
  14. Jung JM, Kim HJ, Ahn H, Ahn IM, Do Y, Choi JY, Seo WK, Oh K, Cho KH, Yu S (2015) Chronic kidney disease and intravenous thrombolysis in acute stroke: a systematic review and meta-analysis. J Neurol Sci 358:345–350.  https://doi.org/10.1016/j.jns.2015.09.353 CrossRefPubMedGoogle Scholar
  15. Khatri M, Himmelfarb J, Adams D, Becker K, Longstreth WT, Tirschwell DL (2014) Acute kidney injury is associated with increased hospital mortality after stroke. J Stroke Cerebrovasc Dis 23:25–30.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.06.005 CrossRefPubMedGoogle Scholar
  16. Kumai Y, Kamouchi M, Hata J, Ago T, Kitayama J, Nakane H, Sugimori H, Kitazono T, For the FSR Investigators (2012) Proteinuria and clinical outcomes after ischemic stroke. Neurology 78:1909–1915.  https://doi.org/10.1212/WNL.0b013e318259e110 CrossRefPubMedGoogle Scholar
  17. Laible M, Mohlenbruch MA, Pfaff J, Jenetzky E, Ringleb PA, Bendszus M, Rizos T (2017) Influence of renal function on treatment results after stroke thrombectomy. Cerebrovasc Dis 44:351–358.  https://doi.org/10.1159/000481147 CrossRefPubMedGoogle Scholar
  18. Lyrer PA, Fluri F, Gisler D, Papa S, Hatz F, Engelter ST (2008) Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology 71:1548–1550.  https://doi.org/10.1212/01.wnl.0000338459.82173.78 CrossRefPubMedGoogle Scholar
  19. Mafham M, Emberson J, Landray MJ, Wen CP, Baigent C (2011) Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One 6:e25920.  https://doi.org/10.1371/journal.pone.0025920 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Martin U, Sponer G, Strein K (1993) Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. Drug Metab Dispos 21:236–241PubMedGoogle Scholar
  21. Naganuma M, Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K, Toyoda K (2011) Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis 31:123–129.  https://doi.org/10.1159/000321516 CrossRefPubMedGoogle Scholar
  22. Penko M, Hojs Fabjan T, Bevc S, Kanic V, Hojs R (2014) A prospective study about impact of renal dysfunction and morbidity and mortality on cardiovascular events after ischemic stroke. Cardiol J 21:163–169.  https://doi.org/10.5603/CJ.a2013.0083 CrossRefPubMedGoogle Scholar
  23. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (AnTicoagulation and risk factors in atrial fibrillation) study cohorts. Circulation 127:224–232.  https://doi.org/10.1161/CIRCULATIONAHA.112.107128 CrossRefPubMedGoogle Scholar
  24. Rein P, Saely CH, Muendlein A, Vonbank A, Drexel H (2010) Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease. Atherosclerosis 211:348–352.  https://doi.org/10.1016/j.atherosclerosis CrossRefPubMedGoogle Scholar
  25. Rowat A, Graham C, Dennis M (2014) Renal dysfunction in stroke patients: a hospital-based cohort study and systematic review. Int J Stroke 9:633–639.  https://doi.org/10.1111/ijs.12264 CrossRefPubMedGoogle Scholar
  26. Shi J, Peng H, You S, Liu Y, Xu J, Xu Y, Liu H, Shi R, Cao Y, Liu CF (2018) Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study. Eur J Neurol 25:687–e45.  https://doi.org/10.1111/ene.13575 CrossRefPubMedGoogle Scholar
  27. Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS (2011) Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 10:909–921.  https://doi.org/10.1016/S1474-4422(11)70195-8 CrossRefPubMedGoogle Scholar
  28. Sjøland JA, Sidelmann JJ, Brabrand M, Pedersen RS, Pedersen JH, Esbensen K, Standeven KF, Ariëns RA, Gram J (2007) Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 98:339–345CrossRefGoogle Scholar
  29. Sobolewski P, Kozera G, Kazmierski R, Michalak S, Szczuchniak W, Sledzinska-Dzwigal M, Nyka WM (2013) Intravenous rt-PA in patients with ischaemic stroke and renal dysfunction. Clin Neurol Neurosurg 115:1770–1774.  https://doi.org/10.1016/j.clineuro.2013.04.006 CrossRefPubMedGoogle Scholar
  30. Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, Sethi S, Lee EJC (2011) GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis 58:56–63.  https://doi.org/10.1053/j.ajkd.2011.02.393 CrossRefPubMedGoogle Scholar
  31. Tsagalis G, Akrivos T, Alevizaki M, Manios E, Stamatellopoulos K, Laggouranis A, Vemmos KN (2009) Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant 24:194–200.  https://doi.org/10.1093/ndt/gfn471 CrossRefPubMedGoogle Scholar
  32. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson CO, Kassebaum NJ, Kinfu Y, Kulikoff XR, Kutz M, Kyu HH, Larson HJ, Leung J, Liang X, Lim SS, Lind M, Lozano R, Marquez N, Mensah GA, Mikesell J, Mokdad AH, Mooney MD, Nguyen G, Nsoesie E, Pigott DM, Pinho C, Roth GA, Salomon JA, Sandar L, Silpakit N, Sligar A, Sorensen RJD, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C, VanderZanden A, Vollset SE, Wanga V, Whiteford HA, Wolock T, Zoeckler L, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Abreu DMX, Abu-Raddad LJ, Abyu GY, Achoki T, Adelekan AL, Ademi Z, Adou AK, Adsuar JC, Afanvi KA, Afshin A, Agardh EE, Agarwal A, Agrawal A, Kiadaliri AA, Ajala ON, Akanda AS, Akinyemi RO, Akinyemiju TF, Akseer N, Lami FHA, Alabed S, al-Aly Z, Alam K, Alam NKM, Alasfoor D, Aldhahri SF, Aldridge RW, Alegretti MA, Aleman AV, Alemu ZA, Alexander LT, Alhabib S, Ali R, Alkerwi A’, Alla F, Allebeck P, al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amegah AK, Ameh EA, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson BO, Anderson GM, Antonio CAT, Aregay AF, Ärnlöv J, Arsenijevic VSA, Artaman A, Asayesh H, Asghar RJ, Atique S, Avokpaho EFGA, Awasthi A, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Bärnighausen T, Barregard L, Barrero LH, Basu A, Basu S, Bayou YT, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Belay HA, Bell B, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabé E, Betsu BD, Beyene AS, Bhala N, Bhalla A, Biadgilign S, Bikbov B, Abdulhak AAB, Biroscak BJ, Biryukov S, Bjertness E, Blore JD, Blosser CD, Bohensky MA, Borschmann R, Bose D, Bourne RRA, Brainin M, Brayne CEG, Brazinova A, Breitborde NJK, Brenner H, Brewer JD, Brown A, Brown J, Brugha TS, Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carapetis JR, Cárdenas R, Carpenter DO, Carrero JJ, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Cavalleri F, Cercy K, Cerda J, Chen W, Chew A, Chiang PPC, Chibalabala M, Chibueze CE, Chimed-Ochir O, Chisumpa VH, Choi JYJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Cohen AJ, Colistro V, Colomar M, Colquhoun SM, Cooper C, Cooper LT, Cortinovis M, Cowie BC, Crump JA, Damsere-Derry J, Danawi H, Dandona R, Daoud F, Darby SC, Dargan PI, das Neves J, Davey G, Davis AC, Davitoiu DV, de Castro EF, de Jager P, Leo DD, Degenhardt L, Dellavalle RP, Deribe K, Deribew A, Dharmaratne SD, Dhillon PK, Diaz-Torné C, Ding EL, dos Santos KPB, Dossou E, Driscoll TR, Duan L, Dubey M, Duncan BB, Ellenbogen RG, Ellingsen CL, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Faghmous IDA, Fahimi S, Faraon EJA, Farid TA, Farinha CSS, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Flaxman A, Foigt N, Fowkes FGR, Franca EB, Franklin RC, Friedman J, Frostad J, Fürst T, Futran ND, Gall SL, Gambashidze K, Gamkrelidze A, Ganguly P, Gankpé FG, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebru AA, Geleijnse JM, Gessner BD, Ghoshal AG, Gibney KB, Gillum RF, Gilmour S, Giref AZ, Giroud M, Gishu MD, Giussani G, Glaser E, Godwin WW, Gomez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gosselin RA, Gotay CC, Goto A, Gouda HN, Greaves F, Gugnani HC, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Hafezi-Nejad N, Haile D, Hailu AD, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hancock J, Handal AJ, Hankey GJ, Hao Y, Harb HL, Harikrishnan S, Haro JM, Havmoeller R, Heckbert SR, Heredia-Pi IB, Heydarpour P, Hilderink HBM, Hoek HW, Hogg RS, Horino M, Horita N, Hosgood HD, Hotez PJ, Hoy DG, Hsairi M, Htet AS, Htike MMT, Hu G, Huang C, Huang H, Huiart L, Husseini A, Huybrechts I, Huynh G, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobs TA, Jacobsen KH, Jahanmehr N, Jakovljevic MB, James P, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jibat T, Jimenez-Corona A, Jonas JB, Joshi TK, Kabir Z, Kamal R, Kan H, Kant S, Karch A, Karema CK, Karimkhani C, Karletsos D, Karthikeyan G, Kasaeian A, Katibeh M, Kaul A, Kawakami N, Kayibanda JF, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachandran CN, Khader YS, Khalil IA, Khan AR, Khan EA, Khang YH, Khera S, Khoja TAM, Kieling C, Kim D, Kim YJ, Kissela BM, Kissoon N, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A, Krog NH, Defo BK, Bicer BK, Kudom AA, Kuipers EJ, Kulkarni VS, Kumar GA, Kwan GF, Lal A, Lal DK, Lalloo R, Lallukka T, Lam H, Lam JO, Langan SM, Lansingh VC, Larsson A, Laryea DO, Latif AA, Lawrynowicz AEB, Leigh J, Levi M, Li Y, Lindsay MP, Lipshultz SE, Liu PY, Liu S, Liu Y, Lo LT, Logroscino G, Lotufo PA, Lucas RM, Lunevicius R, Lyons RA, Ma S, Machado VMP, Mackay MT, MacLachlan JH, Razek HMAE, Magdy M, Razek AE, Majdan M, Majeed A, Malekzadeh R, Manamo WAA, Mandisarisa J, Mangalam S, Mapoma CC, Marcenes W, Margolis DJ, Martin GR, Martinez-Raga J, Marzan MB, Masiye F, Mason-Jones AJ, Massano J, Matzopoulos R, Mayosi BM, McGarvey ST, McGrath JJ, McKee M, McMahon BJ, Meaney PA, Mehari A, Mehndiratta MM, Mejia-Rodriguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Micha R, Millear A, Miller TR, Mirarefin M, Misganaw A, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Mohan V, Mola GLD, Monasta L, Hernandez JCM, Montero P, Montico M, Montine TJ, Moradi-Lakeh M, Morawska L, Morgan K, Mori R, Mozaffarian D, Mueller UO, Murthy GVS, Murthy S, Musa KI, Nachega JB, Nagel G, Naidoo KS, Naik N, Naldi L, Nangia V, Nash D, Nejjari C, Neupane S, Newton CR, Newton JN, Ng M, Ngalesoni FN, de Dieu Ngirabega J, Nguyen QL, Nisar MI, Pete PMN, Nomura M, Norheim OF, Norman PE, Norrving B, Nyakarahuka L, Ogbo FA, Ohkubo T, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osman M, Ota E, Ozdemir R, PA M, Pain A, Pandian JD, Pant PR, Papachristou C, Park EK, Park JH, Parry CD, Parsaeian M, Caicedo AJP, Patten SB, Patton GC, Paul VK, Pearce N, Pedro JM, Stokic LP, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Plass D, Platts-Mills JA, Polinder S, Pope CA, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Qorbani M, Quame-Amaglo J, Quistberg DA, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajavi Z, Rajsic S, Raju M, Rakovac I, Rana SM, Ranabhat CL, Rangaswamy T, Rao P, Rao SR, Refaat AH, Rehm J, Reitsma MB, Remuzzi G, Resnikoff S, Ribeiro AL, Ricci S, Blancas MJR, Roberts B, Roca A, Rojas-Rueda D, Ronfani L, Roshandel G, Rothenbacher D, Roy A, Roy NK, Ruhago GM, Sagar R, Saha S, Sahathevan R, Saleh MM, Sanabria JR, Sanchez-Niño MD, Sanchez-Riera L, Santos IS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt MI, Schneider IJC, Schöttker B, Schutte AE, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford KA, Shaddick G, Shaheen A, Shahraz S, Shaikh MA, Shakh-Nazarova M, Sharma R, She J, Sheikhbahaei S, Shen J, Shen Z, Shepard DS, Sheth KN, Shetty BP, Shi P, Shibuya K, Shin MJ, Shiri R, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Silva DAS, Silveira DGA, Silverberg JI, Simard EP, Singh A, Singh GM, Singh JA, Singh OP, Singh PK, Singh V, Soneji S, Søreide K, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Stein DJ, Stein MB, Stranges S, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeke CEI, Tabarés-Seisdedos R, Tabb KM, Takahashi K, Takala JS, Talongwa RT, Tandon N, Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tedla BA, Tefera WM, Have MT, Terkawi AS, Tesfay FH, Tessema GA, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tirschwell DL, Tonelli M, Topor-Madry R, Topouzis F, Towbin JA, Traebert J, Tran BX, Truelsen T, Trujillo U, Tura AK, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uthman OA, Dingenen RV, van Donkelaar A, Vasankari T, Vasconcelos AMN, Venketasubramanian N, Vidavalur R, Vijayakumar L, Villalpando S, Violante FS, Vlassov VV, Wagner JA, Wagner GR, Wallin MT, Wang L, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, White RA, Wijeratne T, Wilkinson JD, Williams HC, Wiysonge CS, Woldeyohannes SM, Wolfe CDA, Won S, Wong JQ, Woolf AD, Xavier D, Xiao Q, Xu G, Yakob B, Yalew AZ, Yan LL, Yano Y, Yaseri M, Ye P, Yebyo HG, Yip P, Yirsaw BD, Yonemoto N, Yonga G, Younis MZ, Yu S, Zaidi Z, Zaki MES, Zannad F, Zavala DE, Zeeb H, Zeleke BM, Zhang H, Zodpey S, Zonies D, Zuhlke LJ, Vos T, Lopez AD, Murray CJL (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet 388:1459–1544.  https://doi.org/10.1016/S0140-6736(16)31012-1 CrossRefGoogle Scholar
  33. Yahalom G, Schwartz R, Schwammenthal Y, Merzeliak O, Toashi M, Orion D, Sela BA, Tanne D (2009) Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 40:1296–1303.  https://doi.org/10.1161/STROKEAHA.108.520882 CrossRefPubMedGoogle Scholar
  34. Yang B, Zhu J, Miao Z, Zhou B, Ge W, Zhao H, Xu X (2015) Cystatin C is an independent risk factor and therapeutic target for acute ischemic stroke. Neurotox Res 28:1–7.  https://doi.org/10.1007/s12640-015-9522-3 CrossRefPubMedGoogle Scholar
  35. Zhang Y, Churilov L, Meretoja A, Teo S, Davis SM, Yan B (2013) Elevated urea level is associated with poor clinical outcome and increased mortality post intravenous tissue plasminogen activator in stroke patients. J Neurol Sci 332:110–115.  https://doi.org/10.1016/j.jns.2013.06.030 CrossRefPubMedGoogle Scholar
  36. Zorrilla-Vaca A, Ziai W, Connolly ES Jr, Geocadin R, Thompson R, Rivera-Lara L (2018) Acute kidney injury following acute ischemic stroke and intracerebral hemorrhage: a meta-analysis of prevalence rate and mortality risk. Cerebrovasc Dis 45:1–9.  https://doi.org/10.1159/000479338 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of ElectrocardiographyThe Affiliated Guangji Hospital of Soochow UniversitySuzhouChina
  3. 3.Department of ElectrocardiographySuzhou Psychiatric HospitalSuzhouChina

Personalised recommendations